vir biotechnology inc shares were down 11 to 2311 on friday after the company swung to a loss in the fourth quarter the stock fell to a threemonth low of 2202 before trimming its loss shares are down 65 yeartodate and down 17 over the last 12 months the san franciscobased commercialstage immunology company reported thursday that it swung to a loss of 1016 million or 52 cents a share from an earnings of 5253 million or 392 a share in the yearearlier period analysts polled by factset expected a smaller loss of 864 million sales plummeted by almost 94 to 494 million from 8127 million in the yearearlier period vir expects to hold phase 2 readouts for its programs associated with hepatitis b hepatitis d and influenza in 2023